Sublocade
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
CanadaPhone Number
(888) 699-5679Website
www.sublocade.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Sublocade
Indivior UK Limited specializes in the development and distribution of SUBLOCADE®, a once-monthly injectable treatment for adults with moderate to severe opioid addiction. The product is designed to be administered by healthcare providers and is part of a comprehensive treatment plan that includes counseling and psychosocial support. Indivior aims to support individuals in their recovery journey by providing resources and information on how to access treatment. Their target clients are adults struggling with opioid addiction who have initiated treatment with oral buprenorphine.Explore more
Popular SearchesSublocadeIndivior PLCSublocade RemsSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sublocade your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Sublocade is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Sublocade has new funding data
Check if Sublocade has recently received funding, and reach out quickly before it becomes old news!
Sublocade, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Sublocade
Click to see if Sublocade had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Sublocade launches new products
Earning: See what the market has to say on Sublocade recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Sublocade
Compare insights from companies similar to Sublocade, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Sublocade
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Sublocade is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sublocade is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sublocade.
Sublocade Tech Stack
A closer look at the technologies used by Sublocade
Sublocade News & Media
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from a new cost impact model published in The Journal of Current Medical Research and Opinion, estimating that the use of extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, may reduce staff time and associated costs in jails and prisons compared with other medications for opioid use disorder (MOUD).New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
RICHMOND, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals (Nasdaq: INDV) today announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing that adherence to SUBLOCADE® (extended-release buprenorphine), a monthly injectable, is associated with meaningfully lower healthcare utilization and medical costs among commercially insured patients with opioid use disorder (OUD). These outcomes were more favorable compNew Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified. Post-hoc analyses indicated the 300-mg monthly maintenance dose performed significantly better than the 100-mg monthly dose in participants...Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with lower rates of infectious disease complications and improved chronic disease management in...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Sublocade
Sign Up For FreeTo access detailed company insights
Indivior UK Limited specializes in the development and distribution of SUBLOCADE®, a once-monthly injectable treatment for adults with moderate to severe opioid addiction. The product is designed to be administered by healthcare providers and is part of a comprehensive treatment plan that includes counseling and psychosocial support. Indivior aims... Read More
